Aardvark Therapeutics Voluntarily Pauses Phase 3 HERO Trial in Prader-Willi Syndrome Due to Cardiac Safety Signals
Key Highlights
- Aardvark Therapeutics, Inc. pauses its pivotal Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome (PWS) due to safety concerns.
- The pause was prompted by reversible cardiac observations at doses above the intended therapeutic range in a healthy volunteer study.
- All ongoing enrollment and dosing in the HERO trial, as well as the open-label extension study, are on hold.
- The company is conducting a comprehensive safety review and evaluating optimal dosing.
- Announcement of topline data from HERO trial will be delayed. Further guidance expected in Q2 2026, instead of the previously targeted Q3 2026.
- ARD-101 has received Orphan Drug and Rare Pediatric Disease Designations from the FDA for PWS.
Detailed Report
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of small-molecule therapeutics targeting metabolic diseases, has announced a voluntary pause of its Phase 3 HERO (Hunger Elimination or Reduction Objective) trial investigating ARD-101 for the treatment of hyperphagia in patients with Prader-Willi Syndrome (PWS).
The decision was made after routine safety monitoring in a healthy volunteer study identified reversible cardiac observations at doses higher than the target therapeutic range. Importantly, these cardiac effects were not observed at the therapeutic doses intended for patients, but out of an abundance of caution, Aardvark has halted all ongoing enrollment and dosing in both the HERO trial (NCT06828861) and the open-label extension (NCT97034) while a thorough data review is conducted.
Dr. Tien Lee, Founder and CEO of Aardvark, emphasized the company’s commitment to patient safety, stating:
“The safety of every patient in our clinical studies is our highest priority, so we will thoroughly evaluate the signals seen at higher than therapeutic doses of ARD-101 in a healthy volunteer study… We are committed to advancing the ARD-101 clinical program and we are evaluating optimal therapeutic dosing levels to support its progress. We will continue to collaborate closely with the FDA and scientific and clinical experts, and we greatly appreciate our partnership with the PWS community as we determine next steps for this program.”
As a result of this pause and ongoing safety evaluation, Aardvark no longer anticipates reporting topline data from the HERO trial in Q3 2026. Investors should note that the company now expects to provide an update and further guidance in the second quarter of 2026.
About ARD-101 and Company Pipeline
ARD-101 is an orally administered, gut-restricted small molecule that acts as a pan-agonist of bitter taste receptors (TAS2Rs) located on the intestinal lining. By activating these receptors, ARD-101 stimulates enteroendocrine cells to release multiple key gut-peptide hormones, including GLP-1 and cholecystokinin (CCK), which are involved in hunger regulation via gut-brain signaling. The drug has shown potential to reduce hunger, both as a standalone therapy and in combination with established GLP-1 drugs. The FDA’s granting of Orphan Drug Designation and Rare Pediatric Disease Designation for ARD-101 in PWS underscores its potential significance.
In addition to ARD-101, Aardvark is developing ARD-201, a fixed-dose combination of ARD-101 and a DPP-4 inhibitor, currently in two Phase 2 studies. This combination is aimed at addressing limitations of currently marketed GLP-1 therapies for obesity and related metabolic conditions.
Potential Impact on Shareholders and Share Price Sensitivity
- Clinical hold on a pivotal trial is a material event and could significantly affect share price due to the uncertainty regarding both timeline and safety profile of ARD-101.
- Delay in topline data means investors will need to wait longer for key efficacy and safety results, possibly affecting short-term valuation and sentiment.
- Regulatory engagement and the company’s proactive stance toward safety may help mitigate long-term risks if resolved positively, but the outcome is uncertain.
- Capital allocation risks: As highlighted in forward-looking statements, further delays could result in the company using up its cash resources sooner than anticipated.
Forward-Looking Statements
This release contains forward-looking statements, including but not limited to the status and progress of the ARD-101 clinical program, expected timing for data reporting, and potential next steps for the HERO trial. These statements are subject to risks and uncertainties, including possible delays in clinical trials, unfavorable outcomes, regulatory hurdles, and reliance on third-party manufacturing and logistics. Investors are advised to consult the company’s most recent SEC filings for a more detailed discussion of risks.
Contact Information
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with their financial advisors before making any investment decisions. The information herein is based on publicly available disclosures from Aardvark Therapeutics as of the date of this article and may be subject to change.
View Aardvark Therapeutics, Inc. Historical chart here
